Chimeric Therapeutics Ltd. (AU:CHM) has released an update.
Chimeric Therapeutics made significant strides in its cell therapy programs, enrolling the first patient in its CHM CDH17 Phase 1/2 trial targeting colorectal and other cancers. The company is also collaborating with partners to expand patient access and manufacturing capabilities. Additionally, Chimeric secured $5 million in capital commitments, signaling strong investor confidence.
For further insights into AU:CHM stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
